Compare Crocs, Inc. (CROX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Crocs, Inc. trades at $129.26 (market cap $6.31B), while IDEXX Laboratories, Inc. trades at $572.55 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.3× Crocs, Inc.'s market cap, and Crocs, Inc. is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| CROX | IDXX | |
|---|---|---|
Market Cap | $6.31B | $46.22B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $766.68 |
52-Week Low | $73.39 | $526.44 |
Enterprise Value | $7.83B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $138.19, up 1.15% today, near its 52-week high. The stock shows bullish technical signals with strong earnings beats in recent quarters, including Q2 2026 EPS of $4.55 versus $4.35 expected. Revenue trends are stable around $4B annually, though 2025 net income was negative due to high taxes. Analysts maintain a buy-heavy consensus with a $140.43 price target.
Outlook is positive with robust profitability margins and valuation support, but risks include tax scrutiny from recent Malta office news and HEYDUDE brand weakness. The stock offers growth potential if execution improves, yet investors face volatility from guidance misses and competitive pressures.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
